Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medpace Holdings ( (MEDP) ) has shared an announcement.
Medpace Holdings reported that first-quarter 2026 revenue rose 26.5% year on year to $706.6 million, with GAAP net income increasing to $123.9 million and EBITDA up 25.9% to $149.4 million, supported by strong cash generation and a modestly expanding backlog. Net new business awards grew 23.7% to $618.4 million, though the net book-to-bill ratio dipped to 0.88x, and the company issued full-year 2026 guidance indicating continued growth while also announcing that President Jesse Geiger will retire effective May 31, 2026, with CEO August Troendle reassuming the president role on an interim basis to manage leadership transition.
On April 21, 2026, Medpace disclosed Geiger’s planned retirement, emphasizing there were no disagreements over operations, policies or practices, and signaling leadership continuity as Troendle steps back into the president position. The combination of double-digit revenue and earnings expansion, strong liquidity, and an orderly executive change suggests Medpace is reinforcing its operational scale and financial resilience while navigating a key leadership transition that will be closely watched by investors and clients.
The most recent analyst rating on (MEDP) stock is a Buy with a $522.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
The score is driven primarily by strong financial performance (steady multi-year growth, high profitability, modest leverage, and excellent free cash flow) and supportive 2026 guidance/backlog visibility from the earnings call. These positives are tempered by weak technical momentum (below key moving averages with negative MACD) and a premium valuation (P/E ~37) that raises execution risk.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization providing Phase I–IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Headquartered in Cincinnati, Ohio, the company focuses on high-science, regulated trials across oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective therapeutics, employing about 6,300 people in 46 countries as of March 31, 2026.
Average Trading Volume: 372,633
Technical Sentiment Signal: Buy
Current Market Cap: $15.09B
See more data about MEDP stock on TipRanks’ Stock Analysis page.